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Abstract: Circulating tumour DNA (ctDNA) is an attractive tool in cancer research, offering many
advantages over tissue samples obtained using traditional biopsy methods. There has been increasing
interest in its application to muscle-invasive bladder cancer (MIBC), which is recognised to be a
heterogeneous disease with overall poor prognosis. Using a range of platforms, studies have shown
that ctDNA is detectable in MIBC and may be a useful biomarker in monitoring disease status
and guiding treatment decisions in MIBC patients. Currently, with no such predictive or prognostic
biomarkers in clinical practice to guide treatment strategy, there is a real unmet need for a personalised
medicine approach in MIBC, and ctDNA offers an exciting avenue through which to pursue this goal.
In this article, we present an overview of work to date on ctDNA in MIBC, and discuss the inherent
challenges present as well as the potential future clinical applications.
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1. Introduction
In the drive towards personalised medicine, circulating tumour DNA (ctDNA) is an invaluable
tool in cancer research, offering unique advantages over tissue samples collected using traditional
biopsy methods. Its collection via a simple blood draw allows serial samples to be conveniently and
safely taken over a course of treatment, thus facilitating the study of tumour dynamics, treatment
resistance, and disease progression. Furthermore, it has been suggested that ctDNA samples are likely
to provide a more representative snapshot of an individual’s cancer compared with biopsy samples
as tumour clones from the primary, micro-, and macro-metastatic deposits are present in a single
sample [1,2].
These advantages have been exploited in numerous studies across various cancers including
colorectal, breast, prostate, and lung malignancies [3–6]. ctDNA levels have been shown to be
associated with disease burden [7,8] and in an analysis of serial samples, increasing levels have
been shown to pre-date radiological progression [4,9,10]. Analysis of sequential samples taken over
a course of treatment have also demonstrated tumour evolution with the emergence of subclones
documented at disease progression [11–13]. In addition to plasma, tumour DNA fragments have also
been detected in other body fluids such as urine and cerebrospinal fluid [14].
There has been a surge of interest in recent years focusing on ctDNA in muscle-invasive bladder
cancer (MIBC); a heterogeneous disease with an aggressive natural history and poor prognosis. With
no predictive or prognostic biomarkers in current clinical practice to guide treatment strategy, there is
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a real need to develop a personalised medicine approach to optimise patient outcomes, and ctDNA
offers an innovative approach to address this challenge.
In this review article, we provide a brief background on ctDNA before summarising research to
date on ctDNA in MIBC, discussing the challenges present and future clinical applications.
2. Circulating Tumour DNA: Background
2.1. Biology of Circulating DNA
It has long been known that plasma contains nucleic acid fragments including those of DNA
(genomic, mitochondrial, and viral), RNA, and micro-RNA; these have been collectively termed
circulating nucleic acids. The mechanism by which nucleic acid fragments are released into the
circulation remains under debate, but is thought to involve apoptosis, necrosis, and secretion [15].
Circulating DNA (cDNA) fragments are typically less than 200 bp in length. They are thought to
undergo hepatic and renal excretion, and the reported half-life of cDNA fragments ranges between
16 min and 2.5 h [9,15,16]. While increased levels of cDNA are seen in malignancy and have been
reported to be associated with tumour burden and prognosis in some cancer sites [17–19], raised levels
are also seen in benign conditions such as pregnancy, trauma, or inflammation, meaning that cDNA
levels alone are not necessarily a specific biomarker in the diagnosis or management of cancer [15].
In the majority of patients with malignancies, cDNA is mainly composed of wildtype, i.e.,
normal DNA, but may also contain fragments derived from the primary tumor, distant metastases,
and micrometastases. The proportion of circulating tumour DNA (ctDNA) fragments (tumour fraction)
has been shown to increase with disease burden [3,4,7], and also to vary between tumour types [7].
Although some patients with very advanced disease have demonstrated high tumour fractions above
50% [11], these are the minority and in numerous studies of metastatic disease, tumour fractions as low
as 0.04% [4,20] have been reported. Indeed, a recent abstract reported an estimated median tumour
fraction of 1.9% in metastatic urothelial cancer [21]. One of the challenges of working with ctDNA,
therefore, is in detecting and quantifying the tumour fraction, particularly in the setting of early disease
where levels may be in region of 0.01% [3].
2.2. Circulating DNA vs. Circulating Tumour DNA
In order to distinguish ctDNA from wildtype DNA, it is necessary to identify and detect somatic
aberrations harboured by the tumour fragments. Quantification of fragments containing aberrations,
which may include single nucleotide variants (SNVs), copy number alterations (CNAs), or structural
variants, is used as a surrogate of tumour fraction.
There are various approaches to achieve this. One strategy is to first identify aberrations present
in a patient’s tumour tissue using either a broad de novo sequencing approach (e.g., whole exome
or whole genome sequencing) or using a pre-determined set of assays or targeted sequencing panels
encompassing known relevant aberrations in the cancer of interest. Aberrations identified in tumour
tissue can then be detected in cDNA using polymerase chain reaction (PCR)-based specific assays
or a focused next generation sequencing (NGS) approach. An alternative is to sequence the cDNA
upfront using either of the approaches described above. However, in order to perform whole genome
or whole exome sequencing on cDNA, a minimum tumour fraction is required, in the order of at least
10–20% [22,23], and so this approach is precluded in a significant proportion of cases where tumour
fraction does not meet this threshold.
While employing a broad sequencing approach allows an overview of aberrations present, allows
assessment of copy number alterations, and supports the design of patient-specific plasma assays, cost
may often be a prohibitive factor, particularly if high levels of coverage are sought to identify low
frequency aberrations with confidence.
A targeted panel or pre-determined set of assays is more cost-effective, but there is the risk that
tumour fraction may be underestimated or ctDNA may not be detected if the individual’s relevant
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mutations are not included in the panel. Furthermore, using specific assays means that mutations
arising over time or under selective pressure from treatment will not be identified unless included on
the panel. There is thus a balance to be achieved in selecting an approach with sufficient breadth and
depth that allows the question being asked to be answered. In the context of MIBC, we shall see that
both approaches have been employed, and we discuss this further in the next section of this review.
In trying to improve detection rates of ctDNA, it has been suggested that as tumour fragments
are shorter than wildtype DNA fragments [24–26], fragment size selection will be enriched for ctDNA
and thus allow very low frequency aberrations to be more readily detected [27]. This approach may be
useful for increasing detection of ctDNA in patients with early disease or rare variants.
Whichever approach is employed, ultra-sensitive techniques are required to detect the low
levels of ctDNA present. Digital PCR techniques such as BEAMing or droplet digital PCR (ddPCR)
have allowed research in this area to progress with sensitivity thresholds of 0.01% [3,28]. However,
these approaches only allow a few aberrations to be interrogated at a time, and thus require a priori
knowledge regarding aberrations to be detected.
3. Muscle-Invasive Bladder Cancer
3.1. Overview
Muscle-invasive bladder cancer is a heterogeneous disease with an overall poor prognosis [29].
Several molecular profiling studies have identified a number of molecular subtypes that are suggested
to have different spectrums of mutations and clinical behaviour [30–32]. Sequencing studies have
demonstrated that it has a high mutational burden, third only to melanoma and lung [30], but yet, in
contrast to other tumour types, there are currently no approved biomarkers to guide its management.
Radical treatment options in MIBC include neoadjuvant platinum-based combination chemotherapy
followed by surgery, or in patients where surgery is deemed unsuitable or a bladder preservation
strategy is being pursued, chemoradiation may be offered as part of a trimodality approach. In the
palliative setting, platinum-based chemotherapy remains the mainstay of treatment, with the recently
approved immune checkpoint inhibitors offering a further line of treatment. There is a real unmet
clinical need for predictive and prognostic biomarkers in MIBC in order to develop a personalised
approach if outcomes are to be improved. ctDNA in MIBC thus promises to be an exciting avenue to
enable researchers to better understand the molecular biology, study treatment resistance and disease
progression, and identify potential therapeutic targets.
3.2. Potential Clinical Applications of ctDNA in MIBC
ctDNA has the potential to be clinically useful at every step of the treatment pathway in MIBC,
from early diagnosis, monitoring or predicting response to treatment in both the radical and palliative
settings, assessing the need for adjuvant treatment, and in monitoring for recurrence or progression.
Currently, one area of particular interest is in predicting and monitoring response to neoadjuvant
chemotherapy. International guidelines [33,34] currently recommend all patients with localised disease
are offered neoadjuvant cisplatin-based chemotherapy. However, up to 60% of patients do not
respond [35,36] and these patients have thus not only been subjected to unnecessary toxicity, but
have also experienced a delay to their definitive treatment, with a potential detrimental effect on
outcome [37]. A minimally invasive biomarker to predict response or more sensitively monitor
response would thus be of huge clinical benefit, and ctDNA offers the potential to achieve this.
4. CtDNA in MIBC
4.1. Overview
Some of the first work on ctDNA in MIBC dates back to 1991 when Sidransky et al. demonstrated
the presence of p53 mutations in the urinary sediment of three patients with MIBC [38]. Over a
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decade later, cDNA and ctDNA levels in plasma were shown to be higher in bladder cancer patients
than in healthy controls [39,40]. Then, there followed a hiatus in publications on ctDNA in MIBC
until Bettegowda et al.’s landmark paper [7], where next generation sequencing was performed on
tumour tissue from three patients with metastatic MIBC as part of a broader pan-cancer cohort. A p53
mutation was identified in each of the patients and was successfully detected in plasma in all three
cases. In this small subset of patients, clinical outcomes were not reported, although the paper overall
reported increased ctDNA levels with advanced disease. In the last two years, there has been a surge
of publications looking at ctDNA in MIBC. Table 1 summarises representative publications including
select poster abstracts as of June 2018. Some of the earlier studies have included superficial, i.e., <T2
disease; non-muscle-invasive bladder cancer (NMIBC), and MIBC in a cohort. However, more recently,
MIBC has been considered separately and this is in keeping with fact that NMIBC and MIBC have
been shown to have different molecular profiles [41].
4.2. ctDNA Is Detectable Using Commercially Available Panels
In 2016, Sonpavde et al. [42] presented work showing that aberrations in cDNA could be detected
in 25/29 (86.2%) patients with metastatic urothelial cancer using a commercially available panel
composed of 68 cancer-related genes. Using the updated, now 73-gene panel (Guardant360), the group
further went on to demonstrate aberrations in plasma from 265/294 (90%) patients with metastatic
lower tract urothelial cancer [43]. TP53 (48%), ARID1A (17%), and PIK3CA (14%) were the most
commonly reported aberrations. They also compared these results from plasma with publically
available data from previous NGS studies reporting aberrations in tumour tissue, and reported similar
results in terms of the frequency of reported aberrations included on the panel.
Using an alternative 62-gene panel (FoundationACT), McGregor et al. [21] found at least one
aberration in plasma of 48/66 (73%) patients with metastatic urothelial cancer. A proportion of their
cohort also had sequencing data on baseline tumour tissue available, and the authors reported an
example where plasma taken at the time of cisplatin resistance showed persistence of ERBB2 and TP53
mutations identified in baseline tumour tissue alongside a new NF1 aberration. This demonstrates a
potential application of ctDNA in furthering our understanding of disease progression and treatment
resistance in MIBC, with the potential ability to monitor patients during treatment for evidence of
response or the emergence of new potential targets.
Of note, both of these ctDNA panels that were used contained at most only 9 of the most frequent
23 gene mutations documented in the TCGA report [30], and omitted many of the chromatin-modifying
gene alterations frequently seen in MIBC, for example, KMT2D and KDM6A (observed in 28% and
26% of TCGA MIBC cases, respectively). ERCC2, which has been put forward as a potential biomarker
of sensitivity to cisplatin chemotherapy [44], is also absent. However, as the primary aim of these
panels is to identify potential targeted therapy options in the clinical setting, it could be argued that
these omissions do not have any clinical impact for MIBC patients, given that there are currently no
associated therapies for these targets. However, in the research setting, the omission of these frequently
mutated genes is a limitation of these panels in the exploration of potential targets and the study of
disease biology.
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Table 1. Representative publications including select poster abstracts as of June 2018.
Reference Year n Cohort Method Key Findings
Bettegowda et al. [7] 2014 3 Metastatic MIBC One-hundred-gene panel on tumour tissue; SafeSeq onplasma for patient-specific aberrations
TP53 mutations detected in tumour tissue of 3/3
patients, and detectable in plasma of all three patients
Sonpavde et al. $ [42] 2016 29
Advanced urothelial cancer
(MIBC = 27/29)
Sixty-eight-gene commercially available panel to
sequence a single plasma sample from each patient
(Guardant360)
Aberrations detected in 86.2% patients
Birkenkamp-Demtröder
et al. [45] 2016 12
NMIBC: six with recurrence
and six with progression
to MIBC
WES/WGS/mate-pair sequencing on tumour tissue;
personalised ddPCR on sequential plasma samples
ctDNA detectable in 10/12; ctDNA detected several
months before clinical diagnosis of progression to MIBC
in 4/6 patients
Christensen et al. [46] 2017 1: 363;2: 468
1: NMIBC
2: Cx (MIBC ≥ 363/468)
ddPCR assays to screen for PIK3CA and FGFR3
hotspots in tissue, urinary supernatant, and plasma
Eleven percent of Cx cohort had ≥1 mutation detected
in tumour tissue. Analysis of 23 paired urine and
plasma showed higher levels of ctDNA in urine. In 27
Cx plasma samples analysed, high levels of ctDNA in
plasma associated with disease recurrence
Vandekerkhove et al. [47] 2017 51
MIBC:
14/51 N0M0 disease;
27/51 N+ve/M1 disease
Bladder cancer-specific targeted panel (50 genes) on
plasma from 44 patients including sequential samples;
WES on plasma from eight patients to assess
mutational burden
ctDNA detected in 25/44 (56.8%) patients with tumour
fractions ranging from 3.9–72.6%; All with tumour
fraction >30% had distant metastatic disease.
Mutational burden derived from targeted sequencing
panel consistent with that from WES
Patel et al. [48] 2017 17 MIBC (starting NAC)
Eight-gene TAm-Seq panel (for SNVs) and shallow
WGS for copy number assessment on tumour tissue,
plasma, urinary cell pellet, and urinary supernatant
Aberration detected in plasma or urine of 10/17
patients pre-NAC. Greater levels of ctDNA detection in
urine. Detection of plasma or urine ctDNA pre-cycle
two NAC associated with disease recurrence
Birkenkamp-Demtröder
et al. [49] 2017 60
MIBC:
50 NAC; 10 palliative
chemotherapy
Three ddPCR assays to screen for PIK3CA and FGFR3
mutation in tumour tissue; WES on tumour tissue and
germline in 24. Personalised ddPCR assays in plasma
for 26 patients
PIK3CA/FGFR3 assays positive in 19/60; ctDNA
detectable in patients prior to clinically detected
recurrence with median lead time 101 days
McGregor et al. $ [21] 2018 66 Metastatic urothelial cancer
Commercially available 62-gene panel to sequence
plasma (FoundationACT)
ctDNA aberrations detected in 48/66 (73%); Estimated
median tumour fraction 1.9%
Barata et al. [50] 2017 22 Metastatic urothelial cancer
Compared sequencing results from tumour tissue and
plasma sequenced using two different commercially
available panels
Concordance between the two tests was 16.4%
Soave et al. [51] 2017 72 Radical Cx(>46/72 MIBC)
Tested 43 regions covering 37 genes for copy number
variations (multiplex ligation dependent
probe amplification)
cDNA had CNV in 48.6% samples; Overall CNV status
not associated with clinical outcome; gain in KLF5,
ZFHX3, and CDH1 associated with reduced
cancer-specific survival
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Table 1. Cont.
Reference Year n Cohort Method Key Findings
Agarwal et al. [43] 2018 369
Metastatic urinary tract cancer
(294/369—lower urinary
tract cancer)
Commercially available 73-gene panel (Guardant360)
used to sequence plasma
Similar aberrations seen when compared with
publically available NGS data on tumour tissue
Cheng et al. $ [52] 2017 26 Metastatic urothelial cancer
Used a 341–468-gene NGS assay (MSK-IMPACT) to
sequence plasma (n = 26) and archival tumour tissue
(n = 15)
ctDNA detected in 69% patients. Interval between
plasma sampling and tissue collection was 35 days to >4
years; Identical tissue and plasma profiles in 20% (3/15)
Abbreviations: MIBC: muscle-invasive bladder cancer; NMIBC: non-MIBC; ctDNA: circulating tumour DNA; NAC: neoadjuvant chemotherapy; WES: whole exome sequencing; WGS:
whole genome sequencing; Cx: cystectomy; NGS: next generation sequencing; CNV: copy number variation; SNV: single nucleotide variation; ddPCR: droplet digital polymerase chain
reaction; N+ve: node positive; M1: distant metastases; TAm-Seq: tagged amplicon sequencing. $: poster abstract.
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The high aberration detection rates of up to 90%, however, are not to be ignored as other groups
using custom, albeit much smaller panels/assays have reported lower ctDNA detection rates. Of note,
the above cohorts were composed exclusively of patients with advanced disease where ctDNA levels
would be expected to be higher and thus more readily detectable. As yet in the literature, there are no
reports of using such commercially available panels to profile patients with non-metastatic disease.
4.3. Using Patient-Specific Assays to Detect ctDNA
4.3.1. In NMIBC Cohorts
In one of the first papers to apply a personalised approach to bladder cancer,
Birkenkamp-Demtröder et al. [45] used whole exome sequencing (WES), whole genome sequencing
(WGS) and/or matepair sequencing to identify mutations in fresh frozen tumour tissue before
designing personalised ddPCR assays for use on urine and plasma in a cohort comprising of 12 patients
with NMIBC with either disease recurrence or progression to MIBC. ctDNA was detectable in 10/12
(83.3%) patients, including those with non-invasive disease only. In 4/6 (66.7%) patients progressing to
muscle-invasive disease, detection of ctDNA pre-dated clinical diagnosis of MIBC by several months.
Christensen et al. [46] also detected ctDNA in patients with NMIBC and MIBC, but used a targeted
approach with ddPCR assays to detect three hotspot mutations in PIK3CA (E545K) and FGFR3 (S249C,
Y373C), first in tumour tissue and then in plasma and urinary supernatant. In 201 urine samples
from patients with NMIBC taken during their disease course, they reported overall higher urinary
ctDNA levels in those later progressing to MIBC when compared with those with no progression.
Kaplan-Meier progression free survival estimates for a subset of 25 showed that those with ctDNA
urinary levels above the median at initial visit had increased progression rates to MIBC (7/13; 54%)
compared with those with ctDNA levels below the median (1/12; 8%; p = 0.036).
However, within their cystectomy cohort of 468 patients, of whom at least 363 had MIBC, only
44/403 (11%; 65 excluded as insufficient material) had at least one mutation detected in tissue using
the PIK3CA and FGFR3 assays. Of those, 27 urine and 27 plasma samples were analysed. A third of
patients (9/27) had detectable ctDNA in plasma. Increased ctDNA levels in plasma were associated
with lower recurrence-free survival and overall survival. ctDNA levels were overall found to be higher
in urine than in plasma [46].
Using the TCGA data portal [53], it can be shown that 62/412 (15%) MIBC patients possess at
least one of the three hotspot mutations tested by Christensen et al. [46], which is slightly higher than
the detection rate of 11% reported. The authors suggest that the procurement of tissue from a tissue
microarray contributed to a low yield of DNA at the tumour tissue screening step, which may have
resulted in missed cases. The subsequent low detection rate (33%) in plasma, despite the use of ddPCR,
likely reflects the fact that as a cystectomy cohort, patients had localised disease with very low ctDNA
fractions. This study highlights the importance of selecting aberrations to capture as many patients
as possible, especially when utilising techniques where only a few aberrations can be interrogated at
one time.
However, despite small numbers and heterogeneous cohorts consisting mainly of NMIBC,
these studies demonstrate proof-of-concept in using both broad and targeted approaches in screening
tumour tissue for aberrations to subsequently detect in plasma and urine in patients with bladder
cancer. The results raise the possibility of using ctDNA to monitor patients with NMIBC for
progression to MIBC. However much work is needed before this can be explored in the setting
of a prospective clinical trial, and one of the key steps will be in determining the optimal aberration
panel with which to identify and quantify ctDNA.
4.3.2. In MIBC Cohorts
Building upon previous work, Birkenkamp-Demtröder et al. [49] used the same three ddPCR
assays for PIK3CA and FGFR3 hotspot mutations in combination with WES to screen diagnostic tumour
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tissue taken at transurethral resection (TUR) in 60 patients with MIBC, comprising of 50 commencing
NAC and 10 commencing palliative chemotherapy. Using the three assays, at least one mutation was
found in 19/60 patients (31.7%). WES was additionally performed on tissue from 24 patients and
aberrations identified in 100%. The authors went on to design 84 personalised assays for 61 genes
for a final cohort of 26 patients. Of note, only 2/26 (7.7%) had aberrations identified using only the
PIK3CA/FGFR3 assays. Plasma and urine samples were tested although longitudinal results were
available only for plasma. Blood was taken at pre-defined time points during treatment and follow-up.
Of the 24 patients proceeding to radical cystectomy following chemotherapy, 12/24 (50%)
relapsed at a median of 275 days. In 6/12 (50%) of relapsing patients, ctDNA was detectable at
a median of 137 days resulting in a median positive lead time of 101 days. However, ctDNA was
also detected at some time point in 50% of patients who remained disease-free post-surgery, so the
presence of ctDNA post-cystectomy is not specific for relapse [49]. However, the authors noted a
significant association between high plasma ctDNA levels in samples taken at one week to four
months post-cystectomy, and disease relapse, thus suggesting that ctDNA may allow more sensitive
detection of disease recurrence post-surgery, and may be useful in the selection of patients for further
treatment. Samples taken before, during, and after treatment for disease relapse were also analysed
with an overall decrease in levels after 2–5 cycles of treatment correlating with radiological response,
and subsequent increase in levels correlating with progression.
While this paper omits some technical details from its methodology, it sets the scene for the
potential use of ctDNA in the post-operative setting to assess risk of recurrence and perhaps guide
decisions on adjuvant treatment. Once again, the importance of selecting an appropriate panel of
aberrations to target is highlighted, given that in 92.3%, personalised assay design was dependent
upon data from whole exome sequencing.
The potential for ctDNA to detect recurrence before clinical or radiological confirmation was
also demonstrated by Patel et al. [48]. In a cohort of 17 MIBC patients embarking on neoadjuvant
platinum-based chemotherapy, the authors performed tagged amplicon sequencing (TAm-Seq) using
a bladder cancer-specific panel of eight genes to detect mutant DNA in TUR tumour tissue, plasma,
urinary cell pellet (UCP), and urinary supernatant (USN). The eight genes were BRAF, CTNNB1,
FGFR3, HRAS, KRAS, NFE2L2, PIK3CA, and TP53, and were anticipated to encompass 72% of patients
based upon TCGA data. A TERT promoter assay did not perform well and so was excluded. They also
performed shallow whole genome sequencing in order to assess copy number alterations (CNAs).
Samples were collected over a median period of 83 days from commencing NAC, with a median of
15 samples per patient. Patients were followed up for a median of 742 days from commencing NAC,
and 588 days after completing definitive therapy.
On sequencing the available tumour tissue from 16 patients, single nucleotide variations (SNVs)
were detected in 12/16 (75%) patients. The most frequent SNVs were in TP53, KRAS, and PIK3CA.
Copy number alterations were identified in all 16 TUR samples, with the most frequent being CDKN2A
loss, E2F3/SOX4 gain, and PPARG gain.
Subsequent testing in plasma, UCP, and USN in the 12 patients with tumour tissue SNVs showed
detection of mutant DNA in 4/12 (33%), 5/12 (42%), and 5/12 (42%), respectively. CNAs were
detected in 4/16 (33%), 8/15 (53%), and 8/16 (50%) of plasma, UCP, and USN samples, respectively.
Of note, shallow WGS on serial samples from five patients showed evidence of tumour evolution
under the selective pressure of NAC. Overall, aberrations were detected in 10/17 (59%) patients in
plasma and urine samples taken prior to commencing NAC. Detection of aberrations at this point
did not predict the response to treatment. However, upon analysing samples taken prior to cycle two
NAC, the authors found that mutant DNA was present in 5/6 (83%) patients that relapsed, but was
not detected in relapse-free patients (specificity 100%, sensitivity 83%). The median lead time over
radiological diagnosis of progression was 243 days. Of note, of the five patients with mutant DNA
present, only one patient had aberrations detected in plasma. Overall, higher levels of detection were
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noted in urine compared with plasma, although no single sample type captured all the aberrations
present [48].
Although this was a relatively small cohort, the comprehensive assessment of plasma and urine
shows great promise for ctDNA as a potential biomarker of response to treatment in the radical
setting, and suggests that assessment of both plasma and urine is warranted at least in the neoadjuvant
setting. In both these studies, it is again demonstrated that the optimal panel of genes and platform to
interrogate MIBC remains unclear with PIK3CA and FGFR3 assays allowing ctDNA analysis in only
7.7%, and a combination of eight TAm-Seq assays and shallow WGS detecting ctDNA in 59%. However,
with sequencing costs continuing to fall, it may be that broad approaches such as WES, which identified
aberrations in 100% of tumour tissue samples, become more accessible. This strategy, however, would
depend upon the availability of contemporary tissue samples and would thus likely necessitate repeat
biopsies, particularly in those previously treated or with relapsed disease, which may be neither
achievable on a practical level nor acceptable to patients.
Another question to consider is whether the identification of aberrations in tumour tissue first
is necessary or indeed useful given potential intra-tumour heterogeneity and tumour evolution over
time. Cheng et al. [52] used the 341–468 gene MSK IMPACT panel to profile plasma samples from
26 patients with metastatic urothelial cancer. At least one mutation was detected in 18/26 (69%).
For 15 patients, archived tumour tissue was also sequenced using the same panel. The interval
between tissue and plasma sampling ranged from 35 days to >4 years, and 11/15 patients had received
treatment during this period. They reported that the tissue and plasma profiles were identical in
only 3/15 (20%) of patients where the interval between samples ranged from 35 days to <1.5 years.
Six out of fifteen (40%) had mutations identified in plasma, but not in tissue, and vice versa in 11/15
(73%). They concluded that the differences may reflect tumour evolution or intratumour heterogeneity.
It may then be that sequencing archived tissue to detect aberrations of interest may not always identify
the most appropriate targets in ctDNA, and may not be the ideal strategy particularly in patients who
have received treatment or demonstrated a change in disease status in the intervening period. In these
situations, upfront analysis of ctDNA is an attractive option, particularly when repeat up to date tissue
biopsies are not possible.
4.4. Using a MIBC-Specific Panel to Sequence Plasma Upfront
Vandekerkhove et al. [47] designed a 50-gene bladder cancer-specific panel based upon published
data on recurrent mutations and copy number changes in bladder cancer, including the TCGA report.
In designing the panel, the authors noted that 98% of patients from the TCGA MIBC dataset (consisting
primarily of subjects with non-metastatic disease) had a non-synonymous mutation in at least one of
the 50 genes included on their panel. With target depth of 500–1000×, aberrations would be detected
in those with tumour fraction of 5% or more.
Fifty-one patients with MIBC were recruited, including 37 with nodal or distant metastases.
Plasma from all those with nodal or distant metastases, and seven with organ-confined disease were
sequenced using the targeted panel. Overall, 25/44 (56.8%) patients demonstrated a ctDNA fraction
above the 2% detection threshold set. The tumour fraction ranged from 3.9 to 72.6% with all samples
demonstrating greater than 30% tumour fraction originating from patients with distant metastatic
disease. In those with tumour fractions between 3.9–30%, 52% had distant metastatic disease. Only one
of the seven patients with localised disease had detectable ctDNA [47]. This association of higher
tumour content with higher disease burden is in keeping with previous work in other tumour types [7].
In three patients with metastatic disease where ctDNA was detected at more than one time-point over
the course of chemotherapy, aberrations identified were consistent [47]. Frequently mutated genes
included TP53, PIK3CA, and ARID1A; over 50% of patients had chromatin-modifying gene aberrations
and this work has demonstrated that like the commercially available panels, upfront NGS analysis of
plasma cDNA can identify potentially actionable aberrations. Of note, the only recurrent mutations
seen were known hotspot regions in ERBB2, PIK3CA, and the TERT promoter. All other mutations
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were unique to individual patients and this highlights the incredible (and challenging) heterogeneity
seen in MIBC.
Whole exome sequencing was also performed on 11 samples with tumour fraction over 25% from
eight patients, with the primary aim of comparing mutation rates derived from the targeted sequencing
data with that from WES data. The WES results correlated with targeted sequencing data, although the
difference in sequencing depth meant that mutations seen on targeted panel were not always called on
exome data [47]. Mutation rates derived from whole exome data and targeted sequencing data were
also correlated, which is of interest given that mutational burden has been put forward as a predictor
of response to immune checkpoint agents. The potential to assess mutational burden on a plasma
sample rather than tissue biopsy is a potential advantage in the clinical trial setting, where patients
may not otherwise be able or willing to undergo an invasive procedure as part of trial entry.
5. Conclusions
In the last two years, significant progress has been made in the field of ctDNA in MIBC and the
knowledge base has grown rapidly. We have seen that ctDNA can be detected, with varying degrees
of sensitivity, in the plasma and urine of patients with localised and metastatic MIBC. The levels
detected have been demonstrated to be associated with tumour burden and while samples taken at
one time-point are able to allow the identification of potentially actionable aberrations, the real value
of ctDNA lies in the ease of obtaining sequential samples. By analysing samples taken over a course
of treatment or during follow-up, early results in small trials suggest that the presence of ctDNA
may indicate minimal residual disease following surgery, or predict for future disease recurrence
with greater sensitivity than that offered by current standard radiological assessment. This is hugely
exciting and the implications are potentially practice changing, but there is much work to be done
before ctDNA can be applied in the clinical setting.
A key challenge is in refining the detection of ctDNA. MIBC is somewhat unique from other cancer
types where ctDNA research is perhaps more established. Whereas a select few assays, for example,
APC or KRAS mutations in colorectal cancer, BRAF in melanoma encompass a significant proportion
of patients, and are thus reliable aberrations to use a surrogate for tumour fraction, the equivalent
targets have yet to be demonstrated in MIBC. While this is in part because of the heterogeneity of the
disease, it is also likely attributable to the fact that the molecular landscape of MIBC was only more
recently explored when compared with other cancer subtypes. It has since been put forward that 90%
MIBC patients have at least one mutation in hotspot regions of PIK3CA, TP53, or the TERT promoter,
and so a panel encompassing these should be of relevance to the vast majority [23]. While these genes
were included in the 50-gene bladder cancer specific panel by Vandekerkhove et al. [47], the detection
threshold set of 2% for tumour fraction likely accounts for their plasma ctDNA detection rate of 56.8%
falling short of the theoretical 90% described. It will be of great interest to see whether more sensitive
methods, for example, ddPCR assays for this three-gene panel, will indeed encompass the majority of
MIBC patients, including those with localised disease where low tumour fractions make detection more
technically challenging. Furthermore, the use of so-called molecular barcodes, as recently explored in
MIBC samples, offer another method to improve detection thresholds [54].
A unique feature of bladder cancer is the availability of ctDNA in urine. We have seen that ctDNA
was more readily detectable in urine in a cohort of patients undergoing neoadjuvant treatment [48],
and it seems reasonable to suggest that this is by virtue of the close proximity of the primary tumour
to urine, i.e., the shedding of tumour DNA fragments directly into urine. It may well be that urinary
ctDNA is most relevant in patients with localised disease, while plasma ctDNA reflects the systemic
burden of disease.
While great promise is shown in the use of ctDNA to detect recurrence earlier than current
standard approaches, an important consideration is also whether or not detecting recurrence earlier
has any impact on clinical outcomes, and this can only be determined through prospective clinical trials.
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MIBC is rapidly catching up with other more established tumour sites in the field of ctDNA
research, and the clinical implications are huge in this poor prognosis disease where there are currently
no biomarkers in everyday clinical use. By fully harnessing the potential of ctDNA, a truly personalised
approach bypassing spatial and temporal barriers in cancer research appears possible and is key in
furthering our understanding of MIBC and ultimately improving clinical outcomes.
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